On September 23, 2026 Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), reported its financial results for the first half year 2026 ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Half 2026 financial review

As of June 30, 2026, the Company’s cash position amounted to €0.1 million.

Noteworthy is the event post balance sheet date (June 30), namely the capital increase with €0.5 million dated July 16, 2026 which has strengthened the cash position.

After due consideration of detailed budgets and estimated cash flow forecasts for the years 2026 and 2027, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into 2027.

Key financial figures for first half 2026, compared with the first half of 2025 and full year 2025, are summarized below:

Selected key financial figures (€ millions) Half Year Half Year Full Year
30-Jun-26 30-Jun-25 31-Dec-25
Revenue – (0,01) 0,02
Employee benefit expense (0,4) (1,4) (3,6)
Other operating expenses (1,0) (2,5) (4,6)
Other income 0,3 0,2 8,3
Operating profit/(loss) (1,2) (3,7) 0,9
Profit/(loss) for the period/year (1,2) (3,7) 0,8
Net cash used in operations (1,5) (3,3) (6,9)
Cash and cash equivalents 0,1 0,8 1,7
The Company’s license and collaboration agreements generated no revenue in the first half of 2026, which is similar to the first half of 2025.

The total employee benefit expenses decreased significantly to €0,4 million for the six-month period ended June 30, 2026, compared to €1,4 million in the same period of 2025. The decrease is primarily attributable to the workforce reduction implemented during 2025.

Other operating expenses amounted to €0,9 million at June 30, 2026, and decreased €1,6 million compared with the same period in 2025. Overall, the reduction in other operating expenses during the first half of 2026 reflects lower external service costs, a decline in research and development spending, and continued cost control across several operational expenditure categories. The decrease is also attributable to the Company’s strategic divestments, notably the disposal of the R&D facility in 2025 and the catheter business in 2026, which resulted in a lower operating cost base and reduced spending requirements compared to the prior-year period.

For the six-month period ended June 30, 2026, other income is mainly related to a marginal gain on the sale of the C-Cath business.

Net loss was €1,2 million, or € (0,027) per share, for the first half of 2026 compared to a net loss of €3,7 million, or € (0,09) per share, for the same period of 2025.

Net cash used in operations was €1,5 million for the first half of 2026 compared to €3,3 million for the first half of 2025.

The interim financial report for first half 2026 of the Company can be found on our website: View Source

(Press release, Celyad, SEP 23, 2026, View Source [SID1234671024])